4.7 Article

Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid

Journal

ANTIVIRAL RESEARCH
Volume 99, Issue 2, Pages 172-179

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2013.05.012

Keywords

Valproic acid; Antiviral; LCMV; Budding

Funding

  1. Spanish grant [BIO2008-0447-C03-01, BIO2011-24351]
  2. NIH [AI077719 JCT]
  3. CSIC
  4. [RTA2011-00036]

Ask authors/readers for more resources

Valproic acid (VPA), a short chain fatty acid commonly used for treatment of neurological disorders, has been shown to inhibit production of infectious progeny of different enveloped viruses including the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). In this study we have investigated the mechanisms by which VPA inhibits LCMV multiplication in cultured cells. VPA reduced production of infectious LCMV progeny and virus propagation without exerting a major blockage on either viral RNA or protein synthesis, but rather affecting the cell release and specific infectivity of LCMV progeny from infected cells. Our results would support the repurposing of VPA as a candidate antiviral drug to combat arenavirus infections. (C) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available